{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-053829","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.678663+00:00","generated_at":"2026-06-18T21:35:26.006216+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MiMedx Q4 net sales $74.4M, up 10.3% YoY; adjusted EBITDA $7.3M; new CEO Capper appointed","bullets":["Q4 net sales $74.4M (+10.3% YoY); full year $267.8M (+3.6%). Highest quarterly since Q4 2019.","Q4 net loss $0.4M vs net income $2.2M in prior year; FY net loss $30.2M vs $10.3M.","Adjusted EBITDA Q4 $7.3M (improved from $3.6M); FY adjusted EBITDA $3.9M (from $18.7M).","Appointed Joseph H. Capper as CEO and Director; Ricci S. Whitlow as COO.","Commenced first registrational trial of mDHACM for knee osteoarthritis; launched EPIFIX in Japan via GUNZE."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-053829","json":"https://secwatch.observer/filing/0001193125-23-053829.json","markdown":"https://secwatch.observer/filing/0001193125-23-053829.md","text":"https://secwatch.observer/filing/0001193125-23-053829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000119312523053829/0001193125-23-053829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000119312523053829/d439845d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:35:26.006216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"334f2c4d57ab57001f4c1143b2702f21569e9b05","claim":"MIMEDX GROUP, INC. reported Full year ended December 31, 2022 results: revenue Net sales of $267.8 million for full year 2022, net income Net loss of $30.2 million for full year 2022, EPS Net (loss) income per common share - basic and diluted of ($0.33).","evidence_excerpt":"Three Months Ended December 31, Twelve Months Ended December 31, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 74,375 $ 67,409 $ 267,841 $ 258,615 Net (loss) income (415 ) 2,215 (30,197 ) (10,285 ) EBITDA 1 2,043 4,427 (20,929 ) 125 Adjusted EBITDA 1 7,317 3,609 3,914 18,726 Net (loss) income per common share - basic $ (0.02 ) $ 0.01 $ (0.33 ) $ (0.15 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1376339/000119312523053829/0001193125-23-053829-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year ended December 31, 2022"},{"label":"Revenue","value":"Net sales of $267.8 million for full year 2022"},{"label":"Net income","value":"Net loss of $30.2 million for full year 2022"},{"label":"EPS","value":"Net (loss) income per common share - basic and diluted of ($0.33)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c27d66078bcb20e1210db7200425b653d5c8c834","claim":"MIMEDX GROUP, INC. reported Fourth quarter ended December 31, 2022 results: revenue Net sales of $74.4 million for fourth quarter 2022, net income Net loss of $0.4 million for fourth quarter 2022, EPS Net (loss) income per common share - basic and diluted of ($0.02).","evidence_excerpt":"Three Months Ended December 31, Twelve Months Ended December 31, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 74,375 $ 67,409 $ 267,841 $ 258,615 Net (loss) income (415 ) 2,215 (30,197 ) (10,285 ) EBITDA 1 2,043 4,427 (20,929 ) 125 Adjusted EBITDA 1 7,317 3,609 3,914 18,726 Net (loss) income per common share - basic $ (0.02 ) $ 0.01 $ (0.33 ) $ (0.15 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1376339/000119312523053829/0001193125-23-053829-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"Net sales of $74.4 million for fourth quarter 2022"},{"label":"Net income","value":"Net loss of $0.4 million for fourth quarter 2022"},{"label":"EPS","value":"Net (loss) income per common share - basic and diluted of ($0.02)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}